Oracle
Which human cell-surface receptor does the SARS-CoV-2 spike protein bind to enter cells? Answer with the receptor's abbreviation only.
Answer
ACE2
- ACE2
- Angiotensin-converting enzyme 2, the human cell-surface receptor named by the source.
- sources
- www.nature.com, doi.org, en.wikipedia.org, hoffmann et al. 2020, cell, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' — identifies ace2 (angiotensin-converting enzyme 2) as the cell-surface receptor bound by sars-cov-2 spike protein for cell entry, hoffmann et al., 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280, 2020 (pmid 32142651), establishing ace2 as the receptor for sars-cov-2 spike protein binding, hoffmann et al., 2020, cell, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', hoffmann et al., cell 181:271-280 (2020), doi:10.1016/j.cell.2020.02.052; uniprot q9byf1 (ace2_human) lists sars-cov-2 spike as a binding partner, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' (doi:10.1016/j.cell.2020.02.052) — identifies ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor' — establishes ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann et al., cell 2020, 'sars-cov-2 cell entry depends on ace2 and tmprss2'; consistent with who/cdc virology summaries, hoffmann m, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 2020 (pmid 32142651); consistent with who/cdc virology summaries identifying ace2 as the spike protein's receptor., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280 (2020)., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280 (2020). https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020 (pmid 32142651), hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020 (pmid 32142651) — establishes ace2 as the receptor bound by the sars-cov-2 spike protein for cell entry., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7102627/, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell 181(2):271-280.e8 (2020)., hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell, 2020. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. (establishes ace2 as the receptor for sars-cov-2 spike protein binding and cell entry, consistent with the original sars-cov receptor identification.), hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8. https://doi.org/10.1016/j.cell.2020.02.052, hoffmann m, et al. (2020) 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280 — establishes ace2 as the human cell-surface receptor bound by the sars-cov-2 spike protein for cell entry, hoffmann m, et al. (2020) 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280. established that sars-cov-2 spike protein binds human ace2 as its cell-entry receptor., hoffmann m, et al. cell 2020 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor'; corroborated by zhou p, et al. nature 2020 'a pneumonia outbreak associated with a new coronavirus of probable bat origin', both establishing ace2 as the sars-cov-2 spike receptor, hoffmann m, et al. cell 2020: sars-cov-2 cell entry depends on ace2 and tmprss2 (https://doi.org/10.1016/j.cell.2020.02.052), hoffmann m, et al. cell. 2020;181(2):271-280.e8 (doi:10.1016/j.cell.2020.02.052) — identifies ace2 as the receptor used by sars-cov-2 spike protein for cell entry, hoffmann m, kleine-weber h, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor', cell 181(2):271-280, 2020 (doi:10.1016/j.cell.2020.02.052), hoffmann m, kleine-weber h, schroeder s, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8., hoffmann m, kleine-weber h, schroeder s, et al. "sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor." cell. 2020;181(2):271-280.e8. doi:10.1016/j.cell.2020.02.052, hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052 — establishes that sars-cov-2 spike protein binds human ace2 (angiotensin-converting enzyme 2) as its cell-entry receptor., hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8., hoffmann m, kleine-weber h, schroeder s, et al. 'sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor.' cell. 2020;181(2):271-280.e8. (also corroborated by cdc/nih descriptions of sars-cov-2 spike protein binding to human ace2 receptor for cell entry.), journals.asm.org, nih research matters, ‘sars-cov-2 may use key carbohydrate to infect cells’ (https://www.nih.gov/news-events/nih-research-matters/sars-cov-2-may-use-key-carbohydrate-infect-cells); nature, ‘structure of the sars-cov-2 spike receptor-binding domain bound to the ace2 receptor’ (https://www.nature.com/articles/s41586-020-2180-5)., pmc.ncbi.nlm.nih.gov, pubmed.ncbi.nlm.nih.gov, rest.uniprot.org, www.ncbi.nlm.nih.gov, www.nih.gov, www.sciencedirect.com, www.uniprot.org
Work
- pinnedblocks 26,084,035 to 26,084,335 to · on Ethereum mainnet
- answered149 of 149 agreed140 needed
#138ACE2from www.nature.com
#1804ACE2from www.nature.com
#480ACE2from www.nature.com
#1893ACE2from journals.asm.org
#446ACE2from www.nature.com144 more
- signed
by the attester 0x5598…2982usable until
Checking the signature in this browser.
- typed data
- the exact bytes a consumer verifies, as JSON
- attester
- 0x5598aa9146215bc13eb26f2c692ad1461fd32982
- signature
- 0xd41d5fbe23c96e61fce54e0d1fd32fef8ab682d0459220039304a2d9c70ddda87384d8e6eb75c9d9c67b1bfc0204840dde9475ba18739a11190d66f02b8d5c071c
- question hash
- 0x351c13b66292a259f065feacba1e71677b1611596ca1627040578ce25610b20d
- answer type
- bytes32
- consumer
- none named; signed for the zero address
- scored
1 batch queuedon Ethereum mainnet
- scores
- settled, waiting for the batcher